HDAC9 and diffuse large B-cell lymphoma: Treatment with the HDAC inhibitor Chidamide in synergy with Rituximab was found to significantly upregulate CD20 and inhibit the growth of diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo, confirming that Chidamide may have application prospects in DLBCB immunotherapy (130).